Blue Jet Healthcare Ltd Stock Price Today (NSE: BLUEJET)
Fundamental Score
Blue Jet Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Blue Jet Healthcare Ltd share price today is ₹505.35, down 0.99% on NSE/BSE as of 17 June 2026. Blue Jet Healthcare Ltd (BLUEJET) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.84K (Cr). The 52-week high for BLUEJET share price is ₹1027.80 and the 52-week low is ₹325.00. At a P/E ratio of 27.92x, BLUEJET is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 30.24% and a debt-to-equity ratio of 0.02.
Blue Jet Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Blue Jet Healthcare Ltd share price chart: 6.00% return over the past month. 52-week high ₹1027.80, 52-week low ₹325.00.
Blue Jet Healthcare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹440.90 | ₹455.00 | ₹434.80 | ₹452.50 | 3.47L (Cr) | |
| ₹449.35 | ₹462.90 | ₹442.60 | ₹446.65 | 3.25L (Cr) | |
| ₹466.40 | ₹468.00 | ₹445.00 | ₹449.35 | 13.91L (Cr) | |
| ₹492.00 | ₹496.85 | ₹468.20 | ₹470.25 | 8.05L (Cr) | |
| ₹480.00 | ₹521.55 | ₹477.85 | ₹499.55 | 33.16L (Cr) | |
| ₹443.00 | ₹485.15 | ₹425.55 | ₹481.40 | 41.70L (Cr) | |
| ₹441.20 | ₹453.45 | ₹438.00 | ₹441.05 | 2.05L (Cr) | |
| ₹440.15 | ₹451.10 | ₹434.15 | ₹439.95 | 2.24L (Cr) | |
| ₹433.95 | ₹441.45 | ₹428.75 | ₹437.55 | 2.69L (Cr) | |
| ₹421.05 | ₹459.00 | ₹419.00 | ₹437.20 | 9.11L (Cr) |
Blue Jet Healthcare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹449.35 | ₹462.90 | ₹434.80 | ₹452.50 | +0.70% | |
| ₹444.55 | ₹521.55 | ₹408.90 | ₹449.35 | +1.08% | |
| ₹335.00 | ₹455.00 | ₹335.00 | ₹444.55 | +32.70% | |
| ₹393.05 | ₹399.90 | ₹325.00 | ₹327.25 | -16.74% | |
| ₹410.05 | ₹453.00 | ₹352.55 | ₹405.30 | -1.16% | |
| ₹532.00 | ₹541.15 | ₹411.10 | ₹417.75 | -21.48% | |
| ₹578.40 | ₹581.05 | ₹512.40 | ₹530.20 | -8.33% | |
| ₹661.00 | ₹688.50 | ₹538.00 | ₹578.45 | -12.49% | |
| ₹638.70 | ₹692.90 | ₹630.15 | ₹656.40 | +2.77% | |
| ₹667.90 | ₹759.50 | ₹628.40 | ₹630.15 | -5.65% | |
| ₹808.00 | ₹825.00 | ₹659.95 | ₹667.85 | -17.35% | |
| ₹879.90 | ₹1027.80 | ₹755.10 | ₹805.95 | -8.40% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Blue Jet is a capacity expansion story masking near-term earnings weakness and promoter selling.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Blue Jet Healthcare's stock surged 9.99% on April 10, 2026, reaching an intraday high of , outperforming the Pharmaceuticals & Biotechnology sector by 8.2 percentage points. This reverses a recent downtrend. However, Q3FY26 results were weak, with net profit down 59.4% YoY to million and revenue declining 39.6% to million. The company held an earnings call on February 13, 2026. A groundbreaking ceremony for a new manufacturing facility in Andhra Pradesh with a planned investment of was held on February 28, 2026.
CORE STORY (THE REAL GAME)
Blue Jet is being priced as a specialty pharmaceutical ingredient play, specifically in contrast media and high-intensity sweeteners, with potential upside from new capacity and R&D investments. However, near-term earnings are volatile.
- Recent price surge of 9.99% on April 10, 2026
- ₹1,000 crore investment in Vizag facility signals future growth
- Hyderabad R&D center expected to commence work from Q3 FY27
- Successful commissioning of Vizag facility
- Positive results from R&D pipeline
- Stabilization of gross margins
- Q3FY26 revenue decline of 39.6% and profit decline of 59.4%
- Promoter selling (down 6.19%)
- Mid-cap: liquidity risk
Promoter: 79.81% (Δ -6.19%) indicates negative sentiment. FII: 1.83% (Δ -0.14%), DII: 3.63% (Δ 2.68%) [cite: brief]
Indian pharma exports are growing, but face pricing pressures and trade uncertainties.
Blue Jet Healthcare commenced groundbreaking ceremony for new Vizag manufacturing facility with Board-approved Phase 1 investment of ₹1,000 crore.
Free Cash Flow 5Y: ₹326.48 Cr [cite: brief] - Profit converting to cash, but needs monitoring
Next 3-6 months hinge on execution of Vizag project and stabilization of earnings. Watch for margin improvement and new product launches.
Primary Thesis Risk
Failure to execute Vizag expansion will crush the narrative.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Blue Jet Healthcare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Blue Jet Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BLUEJET across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (30.24%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (39.75%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (13.86% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (15.67% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (88.76x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹326.48 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-10.64%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-20.54%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-76.50% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Limited Institutional Interest (FII+DII: 5.46%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Blue Jet Healthcare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Blue Jet Healthcare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Blue Jet Healthcare LtdBlue Jet Health...Selected✓ BLUEJET • 544009 | 50.4/100 | ₹505.35₹505 | ₹9839.53₹9839.53 | 27.92Average 27.9 Average | 30.24%Excellent 30.24% Excellent | 39.75%Excellent 39.75% Excellent | 0.02Excellent 0.0 Excellent | 15.67%Excellent 15.67% Excellent | 13.86%Good 13.86% Good | 0.21% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Blue Jet Healthcare Ltd PE Ratio History
Historical price-to-earnings ratio for BLUEJET — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹17.59 | ₹530.20 | 30.1x |
| FY 2024 | ₹9.44 | ₹564.70 | 59.8x |
| FY 2023 | ₹9.23 | ₹368.10 | 39.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Blue Jet Healthcare Ltd Dividend History
Annual cash dividends paid by BLUEJET — dividend yield 0.21%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹17.35 Cr |
| FY 2024 | ₹0.00 Cr |
| FY 2023 | ₹0.00 Cr |
| FY 2022 | ₹0.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Blue Jet Healthcare Ltd Quarterly Performance
Latest quarterly metrics for BLUEJET — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-20.54%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-10.64%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.86%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.67%
Compounded annual net profit growth over 5 years
Blue Jet Healthcare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BLUEJET — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Blue Jet Healthcare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Blue Jet Healthcare Ltd (BLUEJET) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Blue Jet Healthcare Ltd
About BLUEJET (Blue Jet Healthcare Ltd)
Blue Jet Healthcare Ltd is a dynamic force in the pharmaceutical landscape, specializing in the intricate art of crafting high-value pharmaceutical intermediates and active pharmac...eutical ingredients (APIs). Their expertise lies in developing and manufacturing complex molecules that serve as essential building blocks for a wide spectrum of therapeutic applications. Beyond simple production, Blue Jet prides itself on mastering challenging chemistries and navigating the complexities of regulatory compliance, ensuring the quality and purity of its products. They are committed to driving innovation within the pharmaceutical supply chain by delivering specialized intermediates and APIs that empower drug manufacturers to create life-enhancing medications. The company’s core strength stems from its dedication to precision and customization. Blue Jet not only provides established pharmaceutical building blocks but also excels in the development of niche intermediates tailored to the unique needs of its clients. This involves a deep understanding of the evolving demands of the pharmaceutical industry and a commitment to staying ahead of the curve with innovative manufacturing processes. Their focus on customized solutions extends to offering comprehensive support throughout the drug development lifecycle, from early-stage research to large-scale commercial production, forging strong and lasting partnerships with pharmaceutical companies. With a focus on excellence and an unwavering commitment to quality, Blue Jet Healthcare aims to be a reliable and trusted partner for pharmaceutical companies worldwide. They are committed to ensuring the consistent delivery of high-quality pharmaceutical intermediates and APIs that meet stringent regulatory requirements. The company’s drive for continuous improvement in manufacturing processes, combined with a strong dedication to customer satisfaction, positions them as a forward-thinking player in the pharmaceutical industry. By focusing on innovation and reliability, Blue Jet Healthcare is dedicated to contributing to the advancement of healthcare solutions globally.
Company Details
Key Leadership
Corporate Events
BLUEJET Share Price: Frequently Asked Questions
What is the current share price of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd (BLUEJET) trades at ₹505.35 on NSE and BSE. Market cap ₹9.84K (Cr). Educational data only.
What is the P/E ratio of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has a P/E of 27.92x vs industry average 31.77x.
What is the Bull Run score for Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has a Bull Run score of 50.4/100 based on 25+ financial parameters.
Does Blue Jet Healthcare Ltd pay dividends?
Blue Jet Healthcare Ltd has a dividend yield of 0.21%. Past dividends don't guarantee future payments.
What is the ROE of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has ROE of 30.24%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has debt-to-equity of 0.02.
Is Blue Jet Healthcare Ltd a good investment?
Bull Run gives Blue Jet Healthcare Ltd a score of 50.4/100. This is not investment advice — consult a SEBI-registered advisor.